This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter: revenue up 24% year on year, profit after tax down 11%
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 23.9% to Rs 969 crore from Rs 782 crore, while profit after tax fell 11.0% to Rs 73 crore from Rs 82 crore. Earnings before interest, tax, depreciation and amortisation margin fell from 22.8% to 17.9%. Consolidated half year: operating cash flow Rs 237 crore; related-party loans received Rs 80 crore and Rs 156 crore repaid.
Mixed for shares: revenue growth helps, but lower profit and a nearly 5-point margin drop signal earnings pressure despite positive cash flow.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹969.0 Cr | ₹782.0 Cr | +23.9% |
| Operating profit | ₹62.00 Cr | ₹70.00 Cr | −11.4% |
| Profit after tax | ₹73.00 Cr | ₹82.00 Cr | −11.0% |
| EBITDA margin | 17.9% | 22.8% | −4.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.